Thomas Tu - 27 Jan 2023 Form 4 Insider Report for Inari Medical, Inc.

Signature
/s/ Angela Ahmad, attorney-in-fact for Thomas Tu
Issuer symbol
N/A
Transactions as of
27 Jan 2023
Net transactions value
-$602,328
Form type
4
Filing time
31 Jan 2023, 15:28:47 UTC
Previous filing
04 Jan 2023
Next filing
22 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Options Exercise $4,570 +10,000 +12% $0.4570* 95,700 27 Jan 2023 Direct F1
transaction NARI Common Stock Sale $157,406 -2,699 -2.8% $58.32 93,001 27 Jan 2023 Direct F1, F2
transaction NARI Common Stock Sale $127,544 -2,130 -2.3% $59.88 90,871 27 Jan 2023 Direct F1, F3
transaction NARI Common Stock Sale $42,539 -700 -0.77% $60.77 90,171 27 Jan 2023 Direct F1, F4
transaction NARI Common Stock Sale $190,586 -3,071 -3.4% $62.06 87,100 27 Jan 2023 Direct F1, F5
transaction NARI Common Stock Sale $69,641 -1,100 -1.3% $63.31 86,000 27 Jan 2023 Direct F1, F6
transaction NARI Common Stock Sale $19,182 -300 -0.35% $63.94 85,700 27 Jan 2023 Direct F1, F7, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NARI Stock Option Options Exercise $0 -10,000 -6.3% $0.000000 149,584 27 Jan 2023 Common Stock 10,000 $0.4570 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $58.40 to $59.38 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $59.43 to $60.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $60.44 to $61.34 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $61.57 to $62.56 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $62.83 to $63.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $63.83 to $64.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 The balance includes 264 shares acquired under the Company's Employee Stock Purchase Plan.
F9 The option vested with respect to 25% of the underlying shares on April 23, 2020, and vests with respect to the remaining shares in 36 equal monthly installments thereafter.